A single-center observational study of nirsevimab for prevention of RSV infection in preterm infants - Takeaways - MDSpire

A single-center observational study of nirsevimab for prevention of RSV infection in preterm infants

  • By

  • Rina Su

  • Rigonggaowa A

  • Fang Yao

  • Yanbin An

  • Cheng Cai

  • Lei Yun

  • July 8, 2026

  • 0 min

Share

  • 1

    The study evaluated nirsevimab's efficacy in preventing RSV infection in preterm infants at a single center from November 2024 to January 2026.

  • 2

    Nirsevimab immunized infants showed a significantly higher efficacy rate of 98.73% in preventing RSV infections compared to 84.81% in the non-immunized group.

  • 3

    In the non-immunized group, 15.18% of infants developed RSV infections, with some requiring respiratory support and experiencing adverse outcomes.

  • 4

    All RSV-infected infants in the non-immunized group required rehospitalization, averaging 15.5 days, while no rehospitalization occurred in the immunized group.

  • 5

    No significant adverse reactions were reported in the nirsevimab immunized group following the injection.

Original Source(s)

A single-center observational study of nirsevimab for prevention of RSV infection in preterm infants

  • by Rina Su, Rigonggaowa A, Fang Yao, Yanbin An, Cheng Cai, Lei Yun

  • July 8, 2026

Related Content

Memory-focused therapy: an integrated intervention to reduce trauma symptoms, maladaptive cognitive processes, and emotional distress in Afghan youth

Case Report: Pediatric ACTH-secreting pituitary adenoma presenting with hypertension and anuria

Survival without major morbidity in extremely preterm infants: a prospective multicenter study in Shenzhen, China